Balchem (NASDAQ:BCPC), the Montvale, New Jersey-based leader in specialty health and nutrition ingredients, reported record-breaking fourth-quarter and full-year 2025 results on Friday.
Driven by a global shift toward "better-for-you" consumer trends and robust performance in its human nutrition segment, the company surpassed the $1 billion annual revenue threshold for the first time in its history.
For the full year ended December 31, 2025, Balchem reported record net sales of $1.037 billion, a 11.5% increase compared to 2024.
Profitability reached new heights with record adjusted EBITDA of $274.9 million, up 9.8% year-over-year.
The company’s efficiency gains and pricing discipline translated into a record $173.6 million in free cash flow, providing the fire power for significant capital returns and strategic reinvestment.
The fourth quarter mirrored this strength, with net sales climbing 9.8% to $263.6 million.
GAAP net earnings for the period were $39.2 million, while diluted earnings per share (EPS) for the full year reached $4.75.
CEO Ted Harris attributed the performance to strong organic growth across all three business segments—Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products—noting that the company’s alignment with global health priorities has never been stronger.
In a major win for long-term investors, Balchem announced a 10.3% increase in its annual dividend to $0.96 per share.
This marks the 17th consecutive year of dividend increases, underscoring the Board's confidence in the company's "cash-generative" business model.
Looking toward 2026, Balchem is set to expand its manufacturing footprint with a new state-of-the-art facility in New York, designed to double its microencapsulation capacity for nutraceuticals.